Dáil Éireann Debate, Wednesday - 21 April 2021
2264. Deputy David Cullinane asked the Minister for Health the status of the medication PCBD-110; if it will be approved for addition to the medical cannabis access programme or otherwise approved for prescription and reimbursement; and if he will make a statement on the matter. [20341/21]
Amharc ar fhreagraProspective suppliers of products to the Medical Cannabis Access Programme (MCAP) can apply to the Health Products Regulatory Authority (HPRA), acting on behalf of the Minister for Health, to have a cannabis product considered for inclusion in the schedule to the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) Regulations 2019.
Applicants must provide evidence to demonstrate that the proposed cannabis product meets the requirements of a ‘specified controlled drug’ as defined in the MCAP legislation. The onus is on prospective suppliers to submit applications to the HPRA.
Reimbursement is a matter for the Primary Care Reimbursement Centre (PCRS) in the HSE.
